Stokes Capital Advisors LLC Increases Holdings in Johnson & Johnson (JNJ)

Stokes Capital Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 11.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,868 shares of the company’s stock after buying an additional 1,930 shares during the quarter. Johnson & Johnson comprises approximately 1.5% of Stokes Capital Advisors LLC’s investment portfolio, making the stock its 21st biggest holding. Stokes Capital Advisors LLC’s holdings in Johnson & Johnson were worth $2,289,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Laurel Grove Capital LLC raised its holdings in shares of Johnson & Johnson by 25.9% in the second quarter. Laurel Grove Capital LLC now owns 22,369 shares of the company’s stock valued at $2,714,000 after purchasing an additional 4,600 shares during the last quarter. Guardian Investment Management raised its holdings in shares of Johnson & Johnson by 11.5% in the second quarter. Guardian Investment Management now owns 30,673 shares of the company’s stock valued at $3,721,000 after purchasing an additional 3,164 shares during the last quarter. BKD Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.9% in the second quarter. BKD Wealth Advisors LLC now owns 40,057 shares of the company’s stock valued at $4,860,000 after purchasing an additional 732 shares during the last quarter. FormulaFolio Investments LLC raised its holdings in shares of Johnson & Johnson by 106.3% in the second quarter. FormulaFolio Investments LLC now owns 12,016 shares of the company’s stock valued at $1,458,000 after purchasing an additional 6,191 shares during the last quarter. Finally, Lodestar Investment Counsel LLC IL raised its holdings in shares of Johnson & Johnson by 0.5% in the second quarter. Lodestar Investment Counsel LLC IL now owns 217,894 shares of the company’s stock valued at $26,439,000 after purchasing an additional 1,007 shares during the last quarter. 66.62% of the stock is currently owned by hedge funds and other institutional investors.

Shares of JNJ opened at $138.22 on Friday. The firm has a market cap of $371.96 billion, a P/E ratio of 18.93, a PEG ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, topping the Zacks’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The firm had revenue of $20.83 billion during the quarter, compared to analysts’ expectations of $20.39 billion. During the same period in the previous year, the business posted $1.83 earnings per share. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. analysts predict that Johnson & Johnson will post 8.14 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th were given a dividend of $0.90 per share. The ex-dividend date was Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a yield of 2.60%. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.

A number of analysts have recently issued reports on the stock. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 price objective on shares of Johnson & Johnson in a report on Friday, September 14th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, July 15th. Finally, Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, July 13th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $142.87.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: How to Calculate Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply